An Assessment of the Biological and Clinical Effects of Palbociclib (PD 0332991) with Ovarian Suppression and Letrozole in the Neoadjuvant Treatment of Patients with Premenopausal Estrogen-Receptor Positive/HER2-Negative Primary Breast Cancer
Protocol Chair: Shannon Puhalla, MD
Protocol Officer: Amy Sing, MD
Primary Objective: To determine complete cell cycle arrest (CCCA) as indicated by a Ki67 < 2.7% at 6 weeks as determined centrally at a CAP/CLIA certified laboratory.
Patient Population: Premenopausal patients with estrogen-receptor (ER) positive, HER2-negative, early invasive breast cancer.
Target Accrual: 76 patients
Status: Recruiting participants
The Mission of NSABP Foundation, Inc. is to design and conduct practice changing cancer research, including clinical trials and laboratory studies in the medical, surgical and prevention settings in order to improve the survival outcome and quality of life of patients with breast and colorectal cancer, and to disseminate the results of NSABP collaborative research to benefit the world-wide community.
NSABP Foundation Inc.
Nova Tower 2
Two Allegheny Center – Suite 1200
Pittsburgh, PA 15212-5402